180 related articles for article (PubMed ID: 3196882)
1. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
5. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
Bergsagel DE; Messner H
Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of chronic myeloid leukemia with interferon].
Fülle HH; Dahmen E; Hellriegel KP
Onkologie; 1988 Aug; 11(4):177-83. PubMed ID: 3054669
[TBL] [Abstract][Full Text] [Related]
7. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
Duru F; Tuncer M; Hiçsönmez G
Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
[No Abstract] [Full Text] [Related]
8. CML: new biologic therapies, endpoints and questions.
Martin A; Cheson BD
Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
[No Abstract] [Full Text] [Related]
9. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML.
Shtalrid M; Lugassy G; Rosensaft J; Berrebi A
Leuk Lymphoma; 1993; 11 Suppl 1():193-7. PubMed ID: 8251895
[TBL] [Abstract][Full Text] [Related]
11. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
[TBL] [Abstract][Full Text] [Related]
12. [The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].
Strozha I; Petukhov V; Bondare D; Feldmane G; Duks A; Teilane I; Medne I; Mauritsas M; Grinberga L
Ter Arkh; 1993; 65(10):62-6. PubMed ID: 8296238
[TBL] [Abstract][Full Text] [Related]
13. Interferon alpha induced and maintained complete remission in chronic granulocytic leukemia in relapse after bone marrow transplantation.
Borgies P; Ferrant A; Delannoy A; Van den Berghe H; Michaux JL
Bone Marrow Transplant; 1989 Jan; 4(1):127-8. PubMed ID: 2647178
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
[TBL] [Abstract][Full Text] [Related]
17. [Interferon alfa-2b treatment of adult patients during early chronic phase of Ph1-positive chronic myeloid leukemia (initial report on a cooperative study, protocol CML-MIG-97)].
Khoroshko ND; Turkina AG; Zakharova AV; Kobzev IuN; Domracheva EV; Tikhonova LIu; Semenova EA; Zhuravlev VS; Sokolova MA; Kuznetsov SV
Ter Arkh; 1999; 71(7):42-7. PubMed ID: 10481867
[TBL] [Abstract][Full Text] [Related]
18. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
Von Wussow P; Hehlmann R; Hochhaus T; Jakschies D; Nolte KU; Prümmer O; Ansari H; Hasford J; Heimpel H; Deicher H
J Interferon Res; 1994 Aug; 14(4):217-9. PubMed ID: 7822880
[No Abstract] [Full Text] [Related]
19. Treatment of chronic myelogenous leukemia with interferons: hematologic, cellular, and genetic investigations.
Opalka B; Kloke O; Wandl U; Becher R; Niederle N
Haematol Blood Transfus; 1989; 32():134-8. PubMed ID: 2516494
[No Abstract] [Full Text] [Related]
20. [Cytogenetic remission 10 years after the start of monotherapy with interferon alpha-2b in elderly chronic myelogenous leukemia].
Umeda M; Katoh M; Arai C; Iijima K
Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):520-5. PubMed ID: 14579725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]